ReviewReproductive sciences (Thousand Oaks, Calif.)2026
Research Progress of Histone Deacetylase and Its Inhibitors in Endometriosis.
Review in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Endometriosis is a complex chronic inflammatory disease with an unclear etiology and limited treatment options, severely affecting the reproductive health and quality of life of many women. Histone deacetylases (HDACs), as key epigenetic regulatory molecules, play a significant role in the pathogenesis and progression of endometriosis. This article reviews the abnormal expression of HDACs in endometriosis and their molecular mechanisms in driving the disease by regulating processes such as cell proliferation, apoptosis, inflammation, and epithelial-mesenchymal transition (EMT). It also summarizes the therapeutic potential of histone deacetylase inhibitors (HDACis) such as Vorinostat, Romidepsin, and Butyrate demonstrated in preclinical studies, and analyzes the main challenges currently faced in clinical translation. Finally, this article discusses the challenges and future research directions for developing novel endometriosis therapies targeting HDACs, aiming to provide references for in-depth research and clinical translation in this field.
Indexed as
Identifiers
42717121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.